PTU-062 Vedolizumab: Early Experience and Medium-Term Follow up Data from Two UK Tertiary IBD Centres

PTU-062 Vedolizumab: Early Experience and Medium-Term Follow up Data from Two UK Tertiary IBD Centres

IntroductionVedolizumab was recently granted NICE approval for moderate-to-severe Crohn’s disease (CD) and ulcerative colitis (UC). Novel pathways agreed by our CCG meant that patients at Guy’s & St. Thomas’ and King’s College Hospitals had early access to vedolizumab.MethodsRecords of patients...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Gut 2016-06, Vol.65 (Suppl 1), p.A82-A83
Hauptverfasser: Samaan, MA, Pavlidis, P, Johnston, E, Warner, B, Digby-Bell, J, Koumoutsos, I, Fong, S, Goldberg, R, Gulati, S, Medcalf, L, Sastrillo, M, Bedwell, T, Brown-Clarke, C, Bidwell-Sullivan, J, Forsyth, K, Lee, E, Stanton, A, Duncan, J, Chung-Faye, G, Dubois, P, Powell, N, Anderson, S, Sanderson, J, Hayee, B, Irving, P
Format: Artikel
Sprache:eng
Schlagworte:
Clinical trials
Crohn's disease
Early experience
Inflammatory bowel disease
Patients
Remission
Surgery
Ulcerative colitis
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:IntroductionVedolizumab was recently granted NICE approval for moderate-to-severe Crohn’s disease (CD) and ulcerative colitis (UC). Novel pathways agreed by our CCG meant that patients at Guy’s & St. Thomas’ and King’s College Hospitals had early access to vedolizumab.MethodsRecords of patients commencing vedolizumab between Nov 2014–15 were screened. Those completing at least 14 weeks of treatment were included. Clinical activity was assessed using Harvey-Bradshaw Index (HBI) or Simple Clinical Colitis Activity Index (SCCAI) at baseline, 14 and 30 weeks. Response: HBI/SCCAI reduction ≥3. Remission: HBI < 5 or SCCAI
ISSN:0017-5749
1468-3288
DOI:10.1136/gutjnl-2016-312388.147